Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 3,661 shares of the company’s stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at $754,088.20. This trade represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Monday, November 3rd, Houte Hans Van sold 6,284 shares of Nurix Therapeutics stock. The stock was sold at an average price of $12.56, for a total value of $78,927.04.

Nurix Therapeutics Trading Down 6.1%

Shares of NASDAQ:NRIX traded down $1.07 during trading on Friday, reaching $16.52. The company’s stock had a trading volume of 1,561,160 shares, compared to its average volume of 1,267,247. The stock has a market capitalization of $1.27 billion, a PE ratio of -5.43 and a beta of 1.93. The firm’s 50 day simple moving average is $18.50 and its two-hundred day simple moving average is $13.36. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Wednesday, January 28th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.02. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 57.51%. The business had revenue of $13.58 million during the quarter, compared to the consensus estimate of $13.41 million. Research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NRIX has been the subject of several research analyst reports. Wells Fargo & Company reduced their price objective on Nurix Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Thursday. Mizuho lifted their price target on Nurix Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Oppenheimer decreased their price objective on shares of Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Friday, October 10th. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the company an “overweight” rating in a research note on Thursday, January 8th. Finally, Royal Bank Of Canada lifted their price objective on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $29.50.

Institutional Trading of Nurix Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pictet Asset Management Holding SA grew its holdings in shares of Nurix Therapeutics by 75.1% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,467,600 shares of the company’s stock worth $65,780,000 after purchasing an additional 1,487,060 shares during the last quarter. UBS Group AG grew its stake in shares of Nurix Therapeutics by 16.8% in the 4th quarter. UBS Group AG now owns 423,425 shares of the company’s stock valued at $8,032,000 after purchasing an additional 60,879 shares during the last quarter. Vanguard Group Inc. grew its position in Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock valued at $112,862,000 after buying an additional 1,460,736 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Nurix Therapeutics by 23.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,518 shares of the company’s stock worth $313,000 after acquiring an additional 3,118 shares during the period. Finally, Arizona State Retirement System raised its stake in shares of Nurix Therapeutics by 8.2% during the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after buying an additional 1,674 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.